8-KLeadership ChangesRegulation FDExhibits & Filings

TEXAS INSTRUMENTS INC 8-K Report, Executive Changes (Feb 20, 2024)

Filed February 20, 2024For Securities:TXN

Summary

Texas Instruments Inc. (TXN) announced a change to its Board of Directors through an 8-K filing on February 19, 2024, detailing the election of Reginald DesRoches, effective March 1, 2024. Dr. DesRoches will also join the Board's Audit Committee. His appointment brings new expertise to the board, and the company has confirmed his independence, with no disclosed related-party transactions. Investors can expect Dr. DesRoches to receive standard non-employee director compensation, including an initial equity award valued at approximately $230,000 and a pro-rata annual retainer. This appointment is a governance-related event and does not involve immediate financial performance updates, but signals ongoing board refreshment and commitment to independent oversight, particularly within the critical Audit Committee function.

Key Highlights

  • 1Reginald DesRoches elected to Texas Instruments' Board of Directors, effective March 1, 2024.
  • 2Dr. DesRoches appointed to the Board's Audit Committee.
  • 3The Board has determined Dr. DesRoches meets independence requirements.
  • 4No material related-party transactions involving Dr. DesRoches were disclosed.
  • 5Dr. DesRoches will receive standard non-employee director compensation.
  • 6Includes a one-time initial equity award of approximately $230,000 in restricted stock units.
  • 7Will receive a pro-rata annual retainer for director service.

Frequently Asked Questions

Reginald DesRoches is an individual appointed to the Texas Instruments Board of Directors. While the filing doesn't detail his specific background beyond his academic title (Dr.), such appointments typically aim to bring diverse expertise, strategic guidance, and independent oversight to the company's governance. His joining the Audit Committee suggests a focus on financial integrity and risk management.

The primary financial impact relates to director compensation. Dr. DesRoches will receive an initial equity award valued at approximately $230,000 and a pro-rata annual retainer. This is a standard cost for board membership and does not represent a significant immediate financial outlay for the company relative to its overall operations.

This 8-K filing is primarily a governance update related to board composition. It does not directly signal any immediate changes in Texas Instruments' operational strategy or financial performance. However, the addition of new directors, particularly to critical committees like Audit, can contribute to long-term strategic decision-making and oversight.

The Board's determination of independence means that Dr. DesRoches is considered free from any relationships with Texas Instruments that could materially interfere with his independent judgment as a director. This is a key requirement for board members, especially those serving on audit and compensation committees, to ensure objective decision-making and oversight.